Clinical activity of irofulven in hormone refractory prostate cancer.

被引：0
|
作者：
Cvitkovic, E
Kahatt, C
Senzer, N
Tombal, B
Culine, S
Raymond, E
Alexandre, J
Weems, G
MacDonald, J
机构：
[1] Cvitkovic & Associes Consultants, Le Kremlin Bicetre, France
[2] Mary Crowley Med Res Ctr, US Oncol, Dallas, TX USA
[3] UCLC St Luc, Brussels, Belgium
[4] CRLC, Montpellier, France
[5] Inst Gustave Roussy, Villejuif, France
[6] Hop Cochin, F-75674 Paris, France
[7] MGI Pharma Inc, Bloomington, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4766
引用
收藏
页码：447S / 447S
页数：1
相关论文
共 50 条
  • [21] Phase II protocol with docetaxel plus prednisone in patients with hormone refractory prostate cancer.
    Silva, E
    Da Silava, FMC
    Da Silava, FEC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 449S - 449S
  • [22] A combination docetaxel-capecitabine in patients (pts) with hormone refractory advanced prostate cancer.
    Ferrero, J
    Berdah, JF
    Chamorey, E
    Oudard, S
    Dides, S
    Lesbats, G
    Cavaglione, G
    Nouyrigat, P
    Foa, C
    Guillet, P
    Kaphan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 412S - 412S
  • [23] Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer
    Chiappino, Isabella
    Destefanis, Paolo
    Addeo, Alfredo
    Galetto, Alessandra
    Cucchiarale, Giuseppina
    Munoz, Fernando
    Zitella, Andrea
    Ferrando, Ugo
    Fontana, Dario
    Ricardi, Umberto
    Tizzani, Alessandro
    Bertetto, Oscar
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 234 - 238
  • [24] The impact of age on clinical outcomes in men with hormone refractory prostate cancer
    Halabi, S
    Small, EJ
    Ou, S
    Vogelzang, NJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 408S - 408S
  • [25] Assessment of hormone refractory prostate cancer
    Newling, D
    Fossa, SD
    Andersson, L
    Abrahamsson, PA
    Aso, Y
    Eisenberger, MA
    Khoury, S
    Kozlowski, JS
    Kelly, K
    Scher, H
    HartleyAsp, B
    UROLOGY, 1997, 49 (4A) : 46 - 53
  • [26] Chemotherapy for hormone refractory prostate cancer
    Gridneva, Ya. V.
    Matveev, V. B.
    Bukharkin, B. V.
    Kupchan, D. Z.
    ONKOUROLOGIYA, 2010, 6 (04): : 54 - 60
  • [27] Hormone-refractory prostate cancer
    Alexandre, I.
    Rixe, O.
    ANNALES D UROLOGIE, 2007, 41 (02) : 47 - 55
  • [28] Chemotherapy of hormone refractory prostate cancer
    Wirth, MP
    Nippgen, J
    UROLOGE A, 2003, 42 (11): : 1453 - +
  • [29] Hormone refractory prostate cancer - Preface
    Pienta, KJ
    UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) : XIII - XIII
  • [30] Hormone-Refractory prostate cancer
    Rini B.I.
    Small E.J.
    Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
12345